Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company’s
Board of Directors has authorized a dividend program under which the
company intends to pay quarterly dividends of $0.43 per share, beginning
in the second quarter of 2015, subject to quarterly declarations by the
Board of Directors.
Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a
privately-held biotechnology company, today announced the signing of a
definitive agreement under which Gilead will acquire Phenex’s Farnesoid
X Receptor (FXR) program comprising small molecule FXR agonists for the
treatment of liver diseases including nonalcoholic steatohepatitis
(NASH). Under the terms of the agreement, Gilead will pay Phenex an
upfront payment plus additional payments based upon achievement of
certain development milestones that may potentially be worth up to $470
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate
presentation will be webcast from two upcoming investor conferences: the
17 th Annual BIO CEO & Investor Conference and the 2015
Leerink Global Healthcare Conference, both taking place in New York.
Drugmaker Gilead Sciences Inc. (GILD) recorded its largest single-session fall since its January 1992 initial public offering Monday after a pharmacy benefit manager dropped the company's Hepatitis C drug in favor of a rival's product.
Gilead Sciences Inc. (GILD) said Tuesday it is buying Phenex Pharmaceuticals AG's Farnesoid X Receptor (FXR) program, which comprises small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). As part of the deal, Gilead will pay the privately-held German company an upfront payment plus additional payments based on certain milestones that could be worth up to $470 million.
By Russ Britt, MarketWatch
Shares drop as investors fear high margins will come to an end
LOS ANGELES (MarketWatch)--The future appeared golden when Gilead Sciences Inc. reported its results Tuesday, with earnings per share blowing past forecasts and revenue beating estimates by more than half a billion dollars.
By Russ Britt, MarketWatch
Retail giant to focus on biotech firm's $1,000-a-day pills
LOS ANGELES (MarketWatch) -- Shares of Gilead Sciences Inc. were up more than 2% Monday after the biotechnology giant scored an exclusive rights deal with the nation's largest drug-store chain, CVS Health Corp., for two Hepatitis C treatments that cost $1,000 per pill or more.
According to a recent survey* by Gillette® [NYSE: PG], 35 percent of
American men say shaving messes are a frequent cause of arguments with
their significant other—more than the 28 percent who cite leaving the
toilet seat up as a reason! With that in mind, Gillette has constantly
strived to revolutionize the way the world shaves, and today, is
continuing that commitment with the launch of the new Gillette Fusion
ProGlide Sensitive 2-in-1 Shave Gel Plus Skin Care that guarantees a
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.